Rebecca Sendak
About Rebecca Sendak
Rebecca Sendak is the Global Head of Large Molecules, specializing in the development and optimization of protein-based treatments and vaccines using advanced technologies.
Title: Global Head of Large Molecules
Rebecca Sendak holds the position of Global Head of Large Molecules. In this role, she oversees the research and development of large molecule treatments, focusing on innovative protein-based therapies and vaccines. Her leadership is central to the progress and optimization of these projects within the organization.
Background in Large Molecule Research and Development
Rebecca Sendak has a strong background in the research and development of large molecules. This includes her involvement in creating protein-based treatments and advanced therapeutic technologies. Her expertise spans across various domains, ensuring the development of effective and innovative medical solutions.
Development and Optimization of Protein-Based Treatments Using SYNTHORIN™ Molecules
One of Rebecca Sendak's significant areas of focus is the development and optimization of protein-based treatments using SYNTHORIN™ molecules. These treatments aim to enhance therapeutic outcomes and provide new options for managing diseases. Rebecca's involvement ensures these treatments are developed with precision and efficacy.
Designing Monoclonal Antibodies for Rapid Disease Protection
Rebecca Sendak works on designing monoclonal antibodies that offer rapid protection against diseases. By focusing on monoclonal antibody therapies, she contributes to developing targeted treatments that can quickly and effectively address various health challenges.
Development of Vaccines Using Advanced Technologies
Rebecca Sendak engages in the development of vaccines using multiple advanced technologies, including inactivated, live-attenuated, polysaccharide-based, recombinant protein, and conjugated-polysaccharide vaccines. Her involvement ensures these vaccines are researched and developed to provide effective immunization solutions.
Collaboration with Data Science Companies for AI Platforms
Rebecca Sendak collaborates with data science companies like Owkin and Exscientia to integrate AI platforms into her research. This collaboration enhances the ability to analyze and utilize data efficiently, leading to the development of more precise and effective treatments.
Utilizing mRNA Technology in Vaccine Development
In her research, Rebecca Sendak utilizes mRNA technology to develop vaccines and address challenges in cancer, immune-mediated diseases, and rare diseases. This innovative approach aims to create advanced vaccines with improved efficacy and safety profiles.
Creation of New Immunotherapies Using Natural Killer Cells
Rebecca Sendak is involved in the creation of new immunotherapies using natural killer cells. These therapies aim to boost the immune system's natural ability to fight off diseases, providing new avenues for treating various health conditions.
Developing Multi-Specific Antibodies for Cancer and Immunological Disorders
Rebecca Sendak works on developing multi-specific antibodies that recognize multiple targets to tackle cancers and immunological disorders. This approach aims to provide more comprehensive and effective treatment options for these complex diseases.
Advanced Protein Degrader Therapies Collaboration
Rebecca Sendak engages in the development of advanced protein degrader therapies through collaborations with companies like Kymera and Nurix. These therapies aim to target and degrade problematic proteins, providing potential new treatments for various diseases.
Development of Immunotherapies Using Proprietary Masking Technology
Rebecca Sendak utilizes proprietary “masking” technology to develop immunotherapies that overcome challenges with T-cell engagers. This technology aims to enhance the effectiveness of T-cell-based treatments, providing new solutions for immunotherapy.